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ABSTRACT
Nucleophosmin (NPM1) is a multifunctional protein that is implicated in the 
pathogenesis of several human malignancies. To gain insight into the role of isolated 
fragments of NPM1 in its biological activities, we dissected the C-terminal domain 
(CTD) into its helical fragments. Here we focus the attention on the third helix of 
the NPM1-CTD in its wild-type (H3 wt) and AML-mutated (H3 mutA and H3 mutE) 
sequences. Conformational studies, by means of CD and NMR spectroscopies, showed 
that the H3 wt peptide was partially endowed with an α-helical structure, but the 
AML-sequences exhibited a lower content of this conformation, particularly the H3 
mutA peptide. Thioflavin T assays showed that the H3 mutE and the H3 mutA peptides 
displayed a significant aggregation propensity that was confirmed by CD and DLS 
assays. In addition, we found that the H3 mutE and H3 mutA peptides, unlike the 
H3 wt, were moderately and highly toxic, respectively, when exposed to human 
neuroblastoma cells. Cellular localization experiments confirmed that the mutated 
sequences hamper their nucleolar accumulation, and more importantly, that the 
helical conformation of the H3 region is crucial for such a localization.
INTRODUCTION
Nucleophosmin 1 (NPM1, also known as B23.1, 
No38 and numatrin) is an abundant multifunctional 
protein belonging to the nucleoplasmin family of 
nuclear chaperones [1, 2]. This protein is present in 
high amounts in the granular region of nucleoli, taking 
part in rRNA maturation processes and it is essential for 
embryonic development. The N-terminal domain is the 
oligomerization domain mainly involved in its chaperone 
activity, it extends for approximately 100 residues and 
displays an eight-stranded β-barrel fold. The central 
portion of NPM1 is an IDR (Intrinsically Disordered 
Region) crucial for DNA/RNA recognition mechanism 
[3–5]. The C-terminal domain (CTD) forms a globular 
structure consisting of a three-helix bundle. NMR 
analysis showed that these three helices span over residues 
243–259 (H1), 264–277 (H2), 280–294 (H3) [6]. 
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The presence of several nuclear import/export 
signals in the NPM1 sequence indicates its propensity 
to act as a nuclear and/or nucleolar shuttling protein. 
Remarkably, it is involved in several biological processes 
such as ribosome biogenesis, tumor suppression and 
nucleolar stress response [7, 8]. While decreased NPM1 
and NPM3 protein levels in the hippocampus at advanced 
stages of Alzheimer’s disease have been described, 
resulting in nucleolar alterations and cell death [9], these 
proteins have been found over-expressed or mutated in 
tumors of different histological origin, including gastric, 
ovarian, bladder and prostate carcinomas as well as in 
various hematological malignancies [4, 5, 10]. Moreover, 
its incidence in the nucleoplasm or in other cellular 
compartments is documented in cells exposed to different 
types of stress [11, 12]. NPM1 has been identified as 
the most frequently mutated gene in acute myeloid 
leukemia (AML) patients, in particular specific mutations 
in the exon 12 of the NPM1 gene occur, accounting for 
approximately 30% of AML cases [2, 13–17]. Although 
these mutations occur exclusively in AML patients, 
their leukemogenic potential remains to be understood. 
It is known that they lead to the aberrant accumulation 
of the protein in the cytoplasm of the leukemic cells 
(hence the term NPM cytoplasmic positive NPMc+, for 
this AML subtype) [16]. The increased export of NPM1 
into the cytoplasm affects multiple cellular pathways and 
could induce leukemia by either loss- or gain-of-function 
mechanisms: mislocation of NPM1 in the cytoplasm can 
cause the loss of its nuclear function and, simultaneously, 
its interactors can be delocalized into the cytoplasm, 
significantly impairing their functions. Additionally, 
NPM1 mutants acquire new properties such as the ability 
to interact and inhibit the cell death activity of caspase-6 
and caspase-8 in the cytoplasm [18]. 
A so-called nucleolar localization signal (NoLS) is 
present in the three-helix bundle of NPM1. Importantly, 
although most of the identified NoLS are formed by 
sequence motifs enriched in consecutive basic residues, 
which are thought to be recognized by specific nucleolar 
hub proteins (including NPM1), the NoLS of NPM1 is 
unique and constituted by the two tryptophan residues in 
helix H3 [19]. AML-associated NPM1 mutations are small 
insertions of a different number of bases at the end of the 
gene, causing a frameshift and generating mutant NPM1 
proteins with altered amino acid sequences. Depending 
on the mutation, the last 5–7 C-terminal residues ((WQ)
WRKSL) are substituted by abnormal sequences of 9–11 
amino acids [15]. These mutations lead to the loss of one 
or two Trp residues, as it is found in the type E and A 
mutated NPM1 proteins, respectively. It has been shown 
that loss of these residues, that are crucial elements of the 
hydrophobic core of the C-terminal domain, impairs the 
folding of the domain [6, 20] and hampers its ability for 
nucleic acids recognition [20–23]. Hence, mutated NPM1 
proteins lose the NoLS [16] and, simultaneously, they 
acquire four additional amino acids at the C-terminus, 
which generate a leucine-rich nuclear export signal (NES) 
able to reinforce Crm1 (XpoI)-dependent nuclear export 
of NPM1 leukemic mutants [24]. These variations account 
for the aberrant and stable cytoplasmic localization of 
mutated NPM1 [1, 6, 25, 26]; indeed in AML patients 
with NPM1 mutations, the protein is largely found in 
the cytosol and only a limited portion is retained within 
nucleoli [1]. This feature characterizes this type of 
leukemia that has been included as a new provisional 
entity in the 2008 World Health Organization classification 
of myeloid neoplasms [14].
In order to gain insight into Structure-Activity 
Relationships (SAR) of isolated protein fragments, our 
previous studies were aimed at dissecting NPM1-CTD 
into three peptides corresponding to the three helices. In 
this way, we obtained information on their conformational 
behavior and their ability to interact with NPM1 biological 
partners [21]. The peptide corresponding to the H1 region 
does assume an α-helical structure, and, from NMR 
studies, helical content was found to be ~39% and stable 
upon increasing time and temperature; furthermore it 
appeared to be able to bind to G-quadruplex structures in 
a cooperative recognition along with its N-terminal IDRs 
[21]. On the other hand, the peptide encompassing the 
H2 region showed an unexpected remarkable tendency 
to form amyloid-like assemblies endowed with fibrillar 
morphology and β-sheet structure, under physiological 
conditions [27]. These aggregates appeared to be toxic 
in in vitro cell viability assays. Moreover, the extension 
of the H2 sequence beyond its N-terminus, including the 
linker loop connecting H2 with H1, delayed aggregation 
and its associated cytotoxicity [27]. 
Here, we combine cellular, biophysical and 
biochemical analyses to gain a deeper understanding of 
the molecular mechanisms involved in NPM1 subcellular 
localization, focusing the attention on the H3 region: this 
region was investigated as an isolated peptide in the wild-
type sequence, as well as in the type A and type E AML-
associated mutated sequences.
RESULTS
Peptides corresponding to the H3 region of NPM1-
CTD (H3 wt, H3 mutE and H3 mutA) were designed 
and, to avoid potential charge effects of the extremities, 
all peptides were acetylated and amidated at the N- and 
C-termini, respectively. All sequences are reported in 
Table 1. They were chemically synthesized with good 
yields by SPPS, using Fmoc methodologies and purified 
by RP-HPLC. Their identity and purity (averaged 
purity > 97%) were assessed by LC-MS (data not shown).
Conformational studies
To evaluate the structural preferences of the H3 
variants in comparison with the wt H3 region within 
the native structure of the CTD, all peptides were 
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characterized by far-UV circular dichroism (far-UV CD) 
and nuclear magnetic resonance (NMR) spectroscopies. 
Far-UV CD spectra were initially acquired in phosphate 
buffer at pH 7.2 (at 100 µM) for freshly prepared 
solutions (Figure 1A). The spectra acquired for H3 wt and 
H3 mutE indicate a mixture of unordered and α-helical 
conformations, as suggested by the presence of a strong 
negative band at ca. 202 nm, a weak negative band at 
222 nm and positive values at ca. 190–193 nm. By contrast, 
the spectrum acquired for H3 mutA lacks a maximum at 
190 nm, has a shift of the first minimum at ca. 200 nm and 
a reduction of the Cotton effect at 222 nm, indicating a 
mixed random coil and α-helical conformations in which 
random coil is highly predominant. These differences are 
in agreement with data reported on the entire wt CTD and 
mutated domains [6, 28]. 
As already reported for the H1 region of the NPM1-
CTD [21], the α-helical conformation of the H3 wt peptide 
appeared stable within 4 h at 100 µM (data not shown) and 
upon increasing the temperature from 293 to 371 K, as 
shown by the overlay of the CD spectra collected over this 
range of temperature values (Figure 1B). This suggests 
that the H3 wt peptide retains a significant amount of the 
α-helical structure even at very high temperature, that is 
uncommon for short peptides. The analysis of the chemical 
stability of the H3 wt peptide was checked by using 
urea as a chaotropic agent (Figure 1C). In this case the 
ellipticity measured at 222 nm was significantly affected 
by the addition of even low amounts of the denaturant. 
A similar thermal and chemical stability was shown by the 
H3 mutE peptide (Supplementary Figure S1A and S1C), 
while the H3 mutA counterpart appeared to be more 
flexible, both following thermal and urea concentration 
variations (Supplementary Figure S1B and S1D).
2D-[1H, 1H] NMR spectroscopic analyses were 
performed for H3 wt, H3 mutE and H3 mutA peptides in 
10 mM sodium phosphate, pH 7.2. Comparison of TOCSY 
and NOESY experiments allowed to get resonance 
assignments for most of the proton atoms (Supplementary 
Figure S2 and Supplementary Tables S1–S3). Generally, 
the propensity of a peptide to assume a certain type of 
secondary structure can be derived by analysis of Hα 
chemical shifts; this can be achieved by comparing the 
observed chemical shifts and random coil values [29, 30]. 
For the H3 wt peptide the chemical shift deviations 
from random coil values (CSD) appeared small, but 
negative for most residues, thus indicating a certain 
propensity towards α-helical conformations (Figure 2A). 
The percentage of α-helical content in the wild-type 
peptide was estimated from the CSD values (See Material 
and Methods for details) equal to 21%. The tendency 
of the H3 wt peptide to adopt α-helical conformation 
was confirmed by NOE analysis (Figure 2B), which 
revealed the presence of a few NOE contacts canonical 
for this type of secondary structure, such as Hα(Ala283)-
Hβ(Asp286), Hα(Gln285)-Hββʹ(Trp288), Hα(Leu287)-
Hββʹ(Trp290), Hα(Leu287)-HN(Trp290). A complete 
structure calculation was carried out with the software 
CYANA [31], which produced a structure with a pseudo 
α-helical conformation and tendency to adopt an unordered 
ensemble of conformations (Supplementary Figure S3). 
The majority of NMR conformers tend to adopt disordered 
bend elements in the segment encompassing residues 
Ala283-Arg291 that resemble helical turns. However, the 
number of relevant NOEs is still too small to produce a 
fully ordered and stable conformation. These structural 
calculations do not take into account possible aggregation 
phenomena that may occur at the high concentration used 
to perform the NMR experiments. However, it is worth 
noting that the absence of extensive line broadening in the 
NMR spectra does not point toward the presence of large 
H3 wt aggregates in solution.
We evaluated CSD values for H3 mutA and H3 
mutE peptides as well (Figure 3A and 3B, respectively); 
negative deviations prevail for both peptides but their 
average values are rather small (lower than 0.1 ppm), 
particularly for the H3 mutA peptide, thus indicating a 
relevant amount of random coil content. The α-helical 
contents, evaluated for the H3 mutE and H3 mutA 
peptides from CSD data, were 16% and 10%, respectively. 
Table 1: Peptide sequences analyzed in this study, Leu and Val residues of AML associated NES 
are reported in bold
NAME SEQUENCE MW (amu)
H3 wt 279TDQEAIQDLWQWRKSL294  pI = 4.56 2060.2
H3 mutE 279TDQEAIQDLWQSLAQVSLRK298  pI = 4.56 2373.5
H3 mutA 279TDQEAIQDLCLAVEEVSLRK298  pI = 4.18 2303.5
FITC-H3 wt FITC-βAGRKKRRQRRRPPQGGTDQEAIQDLWQWRKSL 4292.2
FITC-H3 mutE FITC-βAGRKKRRQRRRPPQGGTDQEAIQDLWQSLAQVSLRK 4604.3
FITC-H3 mutA FITC-βAGRKKRRQRRRPPQGGTDQEAIQDLCLAVEEVSLRK 4535.7
FITC-H3 wt 
disordered FITC-βAGRKKRRQRRRPPQGGGKGKPIQDLWQWRKSL 4215.2
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Analysis of NOESY spectra also confirmed prevalence of 
intra-residue and sequential contacts in mutated peptides 
(data not shown), which, however, were not numerous 
enough to determine a structure.
Overall, the far-UV CD and NMR analyses indicate 
that the H3 wt peptide is the most structured, adopting 
a mixture of α-helical and random coil structure. The 
two mutant peptides are less structured, particularly 
in the case of the H3 mutA peptide. The low chemical 
shift dispersions in the 2D [1H, 1H] spectra of the H3 
mutE (Supplementary Figure S2B) and H3 mutA 
(Supplementary Figure S2C) peptides may point out to 
aggregation phenomena. Indeed, the NOESY spectrum of 
the latter is also characterized by line-broadening, typical 
of aggregated species (Supplementary Figure S2C).
Aggregation studies
Both the H3 mutA and H3 mutE peptides are 
expected to have an aggregation propensity higher than the 
H3 wt peptide, on the basis of the bioinformatic analysis 
carried out using the Zyggregator [32] and PASTA [33] 
algorithms (Supplementary Figure S4). To experimentally 
prove these predictions, the time course of Thioflavin T 
(ThT) fluorescence intensity in the presence of a freshly 
prepared solution of peptides was monitored at 100 µM, 
pH 7.2, under constant stirring. H3 mutE and H3 mutA 
peptides showed a clear time-dependent increase of ThT 
fluorescence intensity (Figure 4B and 4C), while the H3 
wt peptide exhibited a weak, if any, higher value of ThT 
fluorescence at t = 0, which did not increase with time 
(Figure 4A). To further corroborate these results, a similar 
experiment was carried out at millimolar concentration for 
H3 mutA and the time dependence of ThT fluorescence 
is reported in Figure 4D. As expected for a nucleation-
dependent growth mechanism, aggregation was faster 
reaching saturation within 60 hours.  
With the aim of evaluating if the observed propensity 
to aggregate of H3 derived peptides is accompanied by a 
conformational transition, CD spectra of the H3-derived 
peptides were monitored at a concentration of 100 µM 
under stirring for 15 days. All H3-derived peptides showed 
a slow and progressive tendency to precipitate and/or 
aggregate over time, presenting a progressive decrease 
of the CD signal (Figure 5A–5C), as we already reported 
for the entire CTD mutA NPM1 [27]. The loss of signal 
for the H3 mutE and H3 mutA peptides was more rapid 
than for the H3 wt counterpart, indicating a more rapid 
aggregation process for the two mutated sequences. 
Moreover, CD spectra of all the H3-derived peptides 
Figure 1: CD analysis of H3 derived peptides. Overlay of CD spectra of (A) freshly prepared solutions of H3 derived peptides, 
(B) H3 wt at increasing temperature and (C) at increasing urea concentration. 
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were also monitored at a higher concentration of 2 mM 
under stirring and only the H3 mutA peptide exhibited a 
characteristic β-sheet far-UV CD spectrum with a broad 
minimum at 218 nm, after 15 days (Figure 5D).
The aggregation of the H3 peptides was further 
investigated by Dynamic Light Scattering (DLS) 
experiments over time at a peptide concentration of 2 mM. 
DLS is a quantitative, optical method for determining 
diffusion coefficients of particles undergoing Brownian 
motion in solution or suspension. The knowledge of 
diffusion coefficient of molecules allows the determination 
of size and flexibility of molecules. DLS is well suited for 
the detection of large aggregates such as amyloid since 
the intensity of the scattered light is proportional to the 
square of the particle mass [34]. As reported in Figure 5E, 
the H3 mutA peptide showed a correct DLS profile after 
15 days with an apparent hydrodynamic radius centered 
at 400 nm. On the contrary, the H3 mutE and H3 wt 
peptides in the same conditions were not able to provide a 
correct correlation function, probably due to the presence 
of monomeric peptides or very small aggregates with 
hydrodynamic diameters less than the size limit of the 
instrument (data not shown). 
Cellular viability experiments
The H3-derived peptides were also evaluated for 
their ability to impair cell viability. We first analyzed 
the effects of the aggregates formed from the H3 
peptides on the mitochondrial status of human SH-SY5Y 
neuroblastoma cells, using the MTT reduction assay. The 
H3 wt, H3 mutA and H3 mutE peptides were incubated at a 
concentration of 1 mM in 50 mM phosphate buffer, pH 7.2, 
at 25°C, at 3 different times (0 h, 15 days and 30 days) and 
then added to the cells at a concentration of 100 µM. The 
three peptides added without pre-incubation (0 h) did not 
affect cell viability at this time-point (Figure 6). Following 
incubation for 15 days, the H3 mutA peptide appeared to 
be toxic; the H3 mutE peptide also appeared to be toxic 
but to a very weak and non-significant extent (Figure 6). 
By contrast, the H3 wt peptide was clearly nontoxic at this 
time. Overall, aggregates of the H3 mutA peptide showed 
a high toxicity at 15 and 30 days of incubation, aggregates 
Figure 2: NMR secondary structure determination of H3 wt. (A) Chemical shift deviations of Hα protons from random coil 
values (∆δHα = δHαobserved − δHαrandom-coil). (B) Summary of relevant sequential and medium-range NOEs. The NOE diagram was produced 
with the software CYANA version 2.1. Cross-peaks in the NOESY 300 spectrum were manually integrated. A NOE contact between the 
Hx and the Hy protons in the i and i + n residues is indicated as dHxHyi,i+n; the thickness of the bar is proportional to the NOE intensity. 
The primary structure is reported on the top of the graph. NMR data were estimated from a H3 wt sample (900 µM final concentration) in 
10 mM sodium phosphate buffer pH = 7.2/D2O 95/5 v/v.
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of the H3 mutE peptide only after 30 days and the H3 wt 
peptide was found to be only weakly toxic at long times of 
incubation (Figure 6).
It is widely accepted that disruption of intracellular 
Ca2+ homeostasis is one of the earliest biochemical 
consequences of the interaction of prefibrillar aggregates 
with cell membranes [35–37]. We therefore investigated 
the effects of aggregated H3 peptides on the intracellular 
Ca2+ content in SH-SY5Y cells. The three peptides added 
without pre-incubation (0 h) did not cause any significant 
Ca2+ influx (Figure 7). Following incubation for 15 days, 
the H3 mutA peptide appeared to cause a significant Ca2+ 
influx; the H3 mutE peptide also had an effect but it was 
very weak and non-significant (Figure 7). By contrast, 
the H3 wt peptide did not affect Ca2+ homeostasis to any 
visible extent at this time. After 30 days of pre-incubation, 
both the H3 mutA and H3 mutE peptides appeared to 
be significantly toxic, whereas the H3 wt counterpart 
appeared only weakly toxic, with a Ca2+ influx that was 
non-significant relative to untreated cells (Figure 7). 
Overall, aggregates of the H3 mutA peptide were found 
to cause a large influx of extracellular Ca2+ ions into the 
cytosol at 15 days and, to an even higher extent, at 30 days 
of incubation; aggregates of the H3 mutE peptide caused 
an effect only after 30 days and the H3 wt peptide was 
found to be substantially harmless both after short and 
long times of incubation (Figure 7). In addition, the rise 
of Ca2+ influx caused by the aggregated peptides showed a 
trend and time dependency similar to that observed for the 
MTT reduction assay.
Cellular localization experiments
NoLSs are short targeting sequences responsible 
for the localization of proteins to the nucleolus and are 
important regulatory elements controlling cellular traffic. 
In NPM1, the NoLS motif is so unusual that is not 
recognized as such by specific algorithms such as NOD 
(Nucleolar localization sequence detector) (http://www.
compbio.dundee.ac.uk/nod) whose analysis is reported 
in Supplementary Figure S5. In order to evaluate the H3-
derived peptides’ subcellular distribution, cell transfection 
experiments and confocal analysis imaging were performed.
We conducted cellular experiments using the three H3 
Figure 3: Chemical shift analysis of AML mutated sequences. Chemical shift deviations of Hα protons from random coil values 
(∆δHα = δHαobserved − δHαrandom-coil) for (A) H3 mutA and (B) H3 mutE in 10 mM sodium phosphate buffer pH = 7.2/D2O 95/5 v/v at a final 
concentration of 900 µM.
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Figure 4: ThT assay for the H3 derived peptides. Time course of ThT fluorescence emission intensity at 480 nm for the (A) H3 wt, 
(B) H3 mutE, and H3 mutA peptides at (C) 100 µM and (D) 2 mM.
Figure 5: CD and DLS analyses of H3 derived peptides over time. (A–C) Overlay of CD spectra of the (A) H3 wt, (B) H3 
mutE, (C) H3 mutA peptides incubated at a concentration of 100 µM under stirring in 10 mM phosphate buffer, pH 7.2, and recorded at 
the indicated times. (D) CD spectrum of the H3 mutA peptide incubated at a concentration of 2 mM under stirring in 10 mM phosphate 
buffer, pH 7.2, and recorded after 15 days. (E) Size distribution of the H3 mutA sample at an equivalent monomer concentration of 2 mM 
recorded after 15 days. 
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derived peptides conjugated to the CPP (Cell Penetrating 
Peptide) corresponding to the fragment 48–60 of the HIV 
Tat protein carrying Fluoresceine isothiocyanate (FITC) 
as a fluorophore (Table 1). It has been reported that this 
sequence, once expressed alone in HeLa cells, is diffusely 
scattered in the cytosol and, to lesser extent, within 
the nucleus, depending on time upon transfection [38]. 
Furthermore, we hypothesized on the importance of the 
wild-type spacing of tryptophan residues for the nucleolar 
localization and of their involvement in a well-defined 
secondary structure. Since the NMR analysis pointed out 
to the involvement of both tryptophan residues in a helical 
turn, we designed a variant of the H3 wt peptide (named H3 
wt disordered) bearing the wild type spacing of Trp288 and 
Trp290 at the C-terminal extremity but with different residues 
in the N-terminal part with a very low predicted α-helical 
content, according to Agadir [39] (Table 1).
HeLa cells were transfected with FITC-containing 
H3 derived-peptides and nuclear staining was detected 
with TO-PRO-3 (Figure 8). The H3 wt peptide localized 
mainly in the nuclei with a clear accumulation within the 
nucleoli. For the H3 wt disordered peptide a pancellular 
distribution could be appreciated with no apparent 
accumulation in any compartment, supporting that the 
specificity of the nuclear localization depends on a well-
defined structural conformation. Both H3 mutated peptide 
sequences resulted distributed between the nuclear 
and the cytoplasmic compartments, with a significant 
accumulation within this latter compartment in all the 
transfected cells. 
DISCUSSION
AML encompasses a heterogeneous group of 
diseases that has traditionally relied on morphology, 
cytochemistry and cytogenetic analysis for classification 
into various subtypes and in turn into different prognostic 
categories. The AML genome contains more than 20 
driver recurrent mutations. The classification of AML 
into prognostic subgroups depending on the specific gene 
mutations, the so-called ‘‘AML with gene mutations’’, 
includes mutations in Fms-like tyrosine kinase 3 (FLT3), 
nucleophosmin 1 (NPM1) and chloramphenicol 
acetyltransferase-box enhancer-binding protein alpha 
(CEBPA) [40]. All resulting mutant NPM1 translation 
products change their nuclear localization signal and a 
shift in the balance of nuclear export occurs, leading to 
the accumulation of NPM1 in the cytoplasm [15, 41–43]. 
AML cells carrying NPM1 mutations always retain 
a certain amount of wild-type NPM1 in the nucleolus 
[16]. This is probably necessary for the survival of 
leukaemic cells [44], since NPM1 mutations in AML 
are always heterozygous and knock-out mice with 
complete deletion of the NPM1 gene die during early 
embryogenesis [10]. Because NPM1 acts in the nucleolus 
as a hub building protein [45], the nucleolus of NPM1-
mutated AML cells may be more vulnerable with respect 
to cells expressing only wild-type NPM1. Indeed AML 
cells are partially depleted of NPM1 as a consequence 
of both NPM1 haploinsufficiency and cytoplasmic 
delocalization of wild type NPM1 protein as complexes 
with the mutants. Thus, mutation-induced changes of the 
levels or the oligomerization status of NPM1 may result 
in defective assembly of the nucleolus in NPM1- mutated 
AML cells, in addition to affecting its functionality and 
the interaction with protein partners. The mechanism 
through which cytoplasmic nucleophosmin contributes to 
leukaemogenesis remains mainly  unknown, but recently 
it has been reported that NPM1 mutations are involved 
in leukemia cell viability and invasion and that Matrix 
metalloproteinases (MMPs) regulated by the K-Ras/ ERK 
MAPK signaling pathway play a role in this process [46].
Figure 6: Cytotoxicity of the H3 derived peptides. Peptides (1 mM monomer concentration) were incubated at 3 different times 
and then added to SH-SY5Y cells at a concentration of 100 µM. The values shown are means ± SEM of three independent experiments 
carried out in triplicate. The single, double and triple asterisks above each bar indicate significant differences (p ≤ 0.05, p ≤ 0.01, p ≤ 0.001, 
respectively) versus untreated cells, unless indicated otherwise.
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Furthermore, NPM1 mutations are stable since 
they are detected during the whole course of the disease 
including relapses and thus represent a suitable target for 
immunotherapy. Indeed, NPM1 mutated sequences have been 
recently studied for their immunogenic properties associated 
with cytoplasmatic localization and for the development of 
immunotherapy for the treatment of AML patients [47–49].
Our recent study outlined the ability of the second 
helix of the CTD of NPM1, H2, to aggregate in an 
amyloid-like manner [27]. We hypothesized that the 
structural destabilization of the CTD in NPM1-AML 
mutants may favor the aggregation through the exposure 
of the amyloidogenic H2 region. Thus, to gain insight into 
the molecular basis of NPM1 transport in physiological 
and pathological conditions, we have carried out a 
biophysical and biochemical study of the third helix of the 
CTD, H3, in wild type as well as AML-mutated versions. 
A combined CD and NMR analysis shows that the region 
Figure 7: Rise in intracellular Ca2+ levels caused by the H3 derived peptides. H3 derived peptides (1 mM monomer 
concentration) were incubated at 3 different times and then added to SH-SY5Y cells at a concentration of 100 µM for 60 min. The green 
fluorescence arises from the intracellular Fluo3 probe bound to Ca2+. The corresponding semi-quantitative values of the green fluorescence 
signals are shown below the images. The values shown are means ± SEM of three independent experiments carried out in triplicate. The 
single, double and triple asterisks indicate significant differences (p ≤ 0.05, p ≤ 0.01, p ≤ 0.001, respectively) versus untreated cells, unless 
indicated otherwise.
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of the sequence corresponding to H3 wt partially adopts 
an α-helical conformation, despite its intrinsic flexibility. 
The NMR analysis shows that the whole H3 wt peptide 
(residues 279–294) exhibits 21% α-helical structure and 
that the segment from Ala283 to Arg291 exhibits a tendency 
to adopt an α-helical structure, involving Trp288 and Trp290. 
CD data indicate that this helical segment is rather stable 
upon temperature increase, that is unusual for a short 
peptide directly derived from a protein region but was also 
observed for the region corresponding to H1 of the CTD 
[21]. CD and NMR data indicate that AML-associated 
mutations of H3 (mutE and mutA sequences) confer 
the H3 region further flexibility that hampers α-helical 
formation and favors aggregation. 
Algorithms that predict the aggregation propensity 
profile of a given sequence suggest the presence of another 
region in NPM1-CTD able to aggregate, in addition to 
H2: the H3 sequences of the leukemic type A and type 
E mutations of NPM1. Our in vitro aggregation results 
on H3 derived peptides and their cytotoxicity confirm 
that the mutated forms of H3 have a higher propensity 
to aggregate than the wt sequence and generate toxic 
aggregates. Hence, the two mutations of type A and type 
E can induce aggregation of the whole CTD by increasing 
the intrinsic aggregation propensity of the H3 region, as 
well as by destabilizing the whole C-terminal domain 
exposing the aggregation potential of the H2 region. Thus, 
the aggregation of the NPM1 mutant A and E could be 
driven from these two distinct regions, H2 and H3, that 
would explain the cellular accumulation phenomena with 
a loss of protein function. 
Overall, our results show that H3 wt does not 
evolve towards amyloid structures for both its ordered 
helical structure and its low propensity to aggregate. 
By contrast, both the mutations present in H3 mutE 
and mutA sequences cause a partial and a complete 
loss of conformational order, respectively, do not alter 
the pI of the peptides and presumably the electrostatic 
interactions among monomers, and introduce new 
hydrophobic residues (such as Leu and Val) that, in 
addition to representing new NES motifs interacting with 
exportin CRM1, cause major insolubility that prompts 
aggregation in disordered states. Furthermore, in mutated 
sequences new H-bonding residues appear (Ser in mutE, 
Figure 8: Subcellular localization the H3 derived peptides. Representative fluorescence microscopy images showing the 
differential subcellular localization of different H3 derived peptides conjugated with a CPP and FITC (H3 wt, H3 mutA, H3 mutE and H3 
wt disordered) in HeLa cells. Nuclei are counterstained with TO-PRO-3; bars, 31.75 µm. The image is representative of all transfected cells, 
of three independent biological replicas, in the field. Left panels show an higher magnification of single cells for each condition.
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Glu in mutA) that may possibly favour intermolecular 
interactions and aggregration. This effect is more apparent 
in the case of Glutamic residues of mutA with respect to 
Serine residues in mutE. 
Moreover, the loss of the unusual aromatic NoLS in 
the H3 region following mutation [50] and the generation 
of a new nucleus export signal (NES) [24], explain why 
NPM1 is translocated from the nucleolus to the cytoplasm. 
Both tryptophan residues appear to be important for 
nucleolar localization, with Trp290 being more critical 
since it is mutated in all the so far identified NPM mutants. 
Furthermore, maximal inhibition of nucleolar binding and 
nucleoplasmic delocalization of mutants are observed 
when both tryptophans are mutated [50]. However the 
mutant sequences did not show a fully cytoplasmatic 
localization. The acquired NES in mutA and mutE 
peptides even if able to recognize CRM1 alone, as recently 
reported [24], need to cooperate with other NES motifs 
within the full-length sequence of NPM1 (residues 42–61 
and 94–102) to fully localize in the cytoplasm the entire 
NMP1-AML associated proteins. Our cellular localization 
experiments also show that the α-helical conformation 
of the H3 region is important in this regard. Hence, the 
importance of the tryptophan residues also within short 
peptide sequences is once again proved and the secondary 
structure in which they are involved is crucial for specific 
nuclear localization. These results highlight our hypothesis 
that the cytosolic accumulation of mutated protein can be 
due to (i) aggregation events of the C-terminal domain (ii) 
and loss and gain of NoLS and NES signals, respectively. 
In conclusion, our results indicate that the two 
AML-associated mutations destabilize the α-helical 
structure of the segment encompassing the H3 α-helix 
in the native NPM1-CTD and predispose it to formation 
of toxic aggregates. In addition, such H3 destabilization 
may contribute to that of the entire NPM1-CTD with 
consequent exposure of the H2 region, which is by far 
the most amyloidogenic region of the whole NPM1-CTD. 
The results also corroborate the hypothesis that the two 
mutations cause the mislocalisation of the NPM1 protein 
from the nucleolus to the cytoplasm and that such as a 
cytosolic accumulation is accompanied by aggregation 
events of the CTD and hetero-oligomerization of the 
N-terminal domain.
MATERIALS AND METHODS
Peptide synthesis
Reagents for peptide synthesis (Fmoc-protected 
amino acids and resins, activation and deprotection 
reagents) were from Novabiochem (Laufelfingen, 
Switzerland) and InBios (Napoli, Italy). Solvents for 
peptide synthesis and HPLC analyses were from Romil 
(Dublin, Ireland); reversed phase columns for peptide 
analysis and the LC-MS system were from Thermo 
Fisher (Milan, Italy). Solid phase peptide syntheses 
were performed on a fully automated multichannel 
peptide synthesizer Syro I (Multisynthech, Germany). 
Preparative RP-HPLC were carried out on a Shimadzu 
LC-8A, equipped with a SPD-M10 AV detector and 
with a Phenomenex C18 Jupiter column (50 × 22 mm 
ID; 10 μm). LC-MS analyses were carried out on a LCQ 
DECA XP Ion Trap mass spectrometer equipped with a 
OPTON ESI source, operating at 4.2 kV needle voltage 
and 320°C with a complete Surveyor HPLC system, 
comprised of MS pump, an autosampler and a photo 
diode array (PDA). Narrow bore 50 × 2 mm C18 BioBasic 
LC-MS columns were used for these analyses. 
The peptide sequences reported in Table 1 were 
synthesized employing the solid phase method on a 
50 μmol scale following standard Fmoc strategies [51]. 
Rink-amide resin (substitution 0.5 mmol/g) was used as 
solid support. Activation of amino acids was achieved 
using HBTU/HOBt/DIEA (1:1:2), whereas Fmoc 
deprotection was carried out using a 40% (v/v) piperidine 
solution in DMF. All couplings were performed for 15 min 
and deprotections for 10 min. At the end of peptide chain 
assembly, all peptides were acetylated at their N-termini. 
Peptides were removed from the resin by treatment with 
a TFA:TIS:H2O (95:2.5:2.5, v/v/v) mixture for 90 min at 
room temperature; then crude peptides were precipitated 
in cold ether, dissolved in a water/acetonitrile (1:1, v/v) 
mixture and lyophilized. 
Products were purified by RP-HPLC applying a 
linear gradient of 0.1% TFA CH3CN in 0.1% TFA water 
from 5% to 65% over 12 min using a semi-preparative 
2.2 × 5 cm C18 column at a flow rate of 20 mL/min. 
Peptides purity and identity were confirmed by LC-MS. 
To perform cellular assays, the fragment 48–60 of the 
HIV Tat protein as CPP (Cell Penetrating Peptide) was 
conjugated to peptides in a stepwise manner and purified 
(Table 1). These conjugated peptides were labelled with 
Fluorescein-βAla at their N-termini. Purified peptides 
were lyophilized and stored at −20°C until use.
CD spectroscopy
CD spectra were recorded on a Jasco J-810 
spectropolarimeter (JASCO, Tokyo, Japan) using a 0.1 cm 
path-length quartz cuvette. CD spectra were registered 
at 25°C in the far UV region from 190 to 260 nm. Each 
spectrum was obtained averaging three scans, subtracting 
contributions from corresponding blanks and converting 
the signal to mean residue ellipticity in units of deg cm2 
dmol-1 res-1. Other experimental settings were: 20 nm/min 
scan speed, 2.0 nm band width, 0.2 nm resolution, 
50 mdeg sensitivity, and 4 sec response. The concentration 
of peptides was kept at 100 µM in 10 mM phosphate 
buffer, pH 7.2. Millimolar samples were centrifuged. 
Thermal variation profiles were obtained by 
measuring the temperature dependence of the ellipticity at 
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222 nm in the 293–371 K range with a resolution of 0.5°C 
and 1.0 nm bandwidth. The heating rate was 1 K/min 
and the response at 16 s with a Peltier temperature 
controller. A buffer solution containing 10 mM of sodium 
phosphate was used in chemical denaturation experiments. 
Urea was purchased from Sigma and further purified by 
recrystallization from ethanol/water (1:1) mixtures. Stock 
solutions of urea were mixed with peptide solutions to 
give a constant final value of the peptide concentration 
(100 µM). The final concentration of denaturant was in the 
range 0.0–8.0 M. Each sample was incubated overnight. 
Longer incubation times led to identical spectroscopic 
signals.
NMR spectroscopy
NMR analysis was performed at 298 K on a Varian 
Unity Inova 600 MHz spectrometer provided with a 
cold-probe. NMR samples consisted of peptides (H3wt, 
H3mutA and H3mutE) dissolved in 600 µL of a mixture 
10 mM sodium phosphate buffer pH = 7.2/ D2O (99.8% d, 
Armar Scientific, Switzerland) 95/5 v/v at a final 
concentration of 900 µM. 
The process of proton resonance assignments was 
carried out with the canonical Wüthrich procedure [52]
based on combined analysis of 2D [1H, 1H] TOCSY (Total 
Correlation Spectroscopy) (70 ms mixing time) [53] and 
NOESY (Nuclear Overhauser Enhancement Spectroscopy) 
(200 and 300 ms mixing times) [54] experiments. TSP 
(Trimethylsilyl-3-propionic acid sodium salt-d4,99% d, Armar 
Scientific, Switzerland) was used as internal standard for 
chemical shifts referencing (See Supplementary Tables S1–S3 
for H3 wt, H3 mutA and H3 mutE, respectively).
1D spectra were acquired with a relaxation delay of 
1s and 32–64 scans. 2D [1H, 1H] experiments were usually 
recorded with 32–64 scans, 128–256 FIDs in t1, 1024 or 
2048 data points in t2. Water suppression was achieved 
by Excitation Sculpting [55]. The software VNMRJ 
(Varian/Agilent Technologies) was implemented for 
spectra processing; the program NEASY [56] (included 
in the CARA (Computer Aided Resonance Assignment) 
software package) (http://www.nmr.ch/)) was used for 
spectra analysis. 
Chemical shift deviations from random coil values 
for Hα protons (CSD) were calculated with the protocol 
suggested by Kjaergaard and collaborators by keeping into 
account the influence of neighbouring amino acids (http://
www1.bio.ku.dk/english/research/pv/sbin_lab/staff/MAK/
randomcoil/script/) [29, 30, 57].
Helical populations were estimated from CSD 
data with the equation: [Δδ
Hαaverage
/(−0.39)] × 100 where 
[(CSD = Δδ
Hα
= δ
Hαobserved
− δ
Hαrandom-coil
)] was averaged 
over all residues in a helical conformation [58]. Peptide 
structure calculations were conducted with the software 
CYANA [31] (version 2.1). Distance constraints for 
structure calculations were generated from a NOESY 
300 ms experiment. Angular constraints were produced 
with the GRIDSEARCH module of CYANA. Calculations 
were initiated from 100 random conformers; the 
10 structures with the lowest target functions were further 
analysed with the program MOLMOL [59].
ThT fluorescence assay
The ThT solution (6.48 µL at 38.5 mM ThT in 
water) was added to 2.5 mL of the peptide stock solutions 
(the final concentrations of ThT and peptides were both 
100 µM) at 25°C. For H3 mutA a similar experiment at 2 
mM was also carried out and the sample was previously 
centrifuged.  ThT fluorescence was measured using a 
Varian Cary Eclipse spectrofluorimeter (Varian, California, 
USA) and a cell consisting of a 10 × 10 mm path-length 
quartz cuvette, under magnetic stirring. Measurements 
were collected every day during 25–30 days, by using 
excitation and emission wavelengths of 440 and 450–600 
nm, respectively.
Dynamic light scattering (DLS)
H3 derived peptides (2 mM monomer concentration, 
and centrifuged), were kept under stirring in 50 mM 
phosphate, pH 7.2, at 25°C. The measurements were 
performed using a Zetasizer Nano S DLS device from 
Malvern Instruments (Malvern, Worcestershire, UK) with 
633 nm laser, dual scattering angle mode, thermostated 
with a Peltier system and using a low-volume (45 μL), 
ultramicro cell. Size distributions by intensity and total 
light scattering intensity were determined in automatic 
mode at regular time-intervals over a period of 10 min for 
each measurement. Thirteen acquisitions were recorded, 
each 10 seconds in duration.
Cell culture and transient transfection with 
synthetic peptides
Human SH-SY5Y neuroblastoma cells (A.T.C.C., 
Manassas, VA) were cultured in DMEM, F-12 Ham with 
25 mM HEPES and NaHCO3 (1:1) and supplemented 
with 10% vol/vol FBS, 1.0 mM glutamine and antibiotics. 
Cell cultures were maintained in a 5.0% vol/vol CO2 
humidified atmosphere at 37°C and grown until they 
reached 80% confluence for a maximum of 20 passages.
HeLa cells were grown in DMEM (Dulbecco’s 
modified Eagle’s medium) supplemented with 10% v/v 
of fetal bovine serum (FBS), 100 U/mL penicillin and 
100 µg/mL streptomycin sulfate. 
For transient peptide transfection, HeLa cells 
were seeded onto glass coverslip at 1 × 105 cells/mL in 
24-well plates overnight. The following day, 10 µM of 
TAT-H3 derived peptides were diluted in DMEM without 
red phenol and sonicated with a Bioruptor instrument 
(Diagenode, Liege, Belgium), 30 sec on/off at the highest 
power for 30 min to avoid aggregates and then incubated 
over cells for 24 h.
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MTT reduction assay
SH-SY5Y cells were seeded in 96-well plates. 
Aggregates of the H3 wt, H3 mutA and H3 mutE peptides 
(1 mM monomer concentration) were incubated in 50 mM 
sodium phosphate buffer, pH 7.2, 25°C under stirring, for 
3 different times (0 h, 15 days and 30 days). The samples 
were then diluted into cell culture media at a 100 µM 
peptide concentration, and then added to the SH-SY5Y 
cells for 24 h at 37°C. Cell viability was then assessed by 
the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) reduction assay as previously described 
[27]. Cell viability was expressed as the percentage of 
MTT reduction in treated cells compared to untreated cells 
(taken as 100%). 
Measurement of intracellular Ca2+
Aggregates of the H3 wt, H3 mutA and H3 mutE 
peptides (1 mM monomer concentration) were incubated 
in 50 mM sodium phosphate buffer, pH 7.2, 25°C under 
stirring, for 0 h, 15 days and 30 days. The samples were 
then diluted in cell culture media at a 100 µM peptide 
concentration, and then added to the SH-SY5Y cells 
seeded on glass coverslips for 60 min at 37°C. The 
cells were then loaded for 30 min at 37°C with 10 μM 
fluo3-AM (Life technologies, CA, USA), as previously 
described [27]. The resulting cell fluorescence was 
analysed by confocal Leica TCS SP5 scanning microscope 
(Mannheim, Germany) equipped with an argon laser 
source for fluorescence measurements at 488 nm and a 
Leica Plan Apo 63× oil immersion objective. A series of 
optical sections (1024 × 1024 pixels) 1.0 μm in thickness 
was taken through the cell depth for each examined 
sample. The confocal microscope was set at optimal 
acquisition conditions, e.g. pinhole diameters, detector 
gain and laser powers. Settings were maintained constant 
for each analysis. To quantify the signal intensity of the 
fluorescent probe between 10 and 22 cells were analysed 
using ImageJ software (NIH, Bethesda, MD) and the 
fluorescence intensities expressed as arbitrary units.
Detection of subcellular localization
For fluorescence analyses, HeLa cells grown on 
glass coverslips were fixed with paraformaldehyde 4% 
v/v in PBS for 20 min at room temperature (RT). Fixed 
cells were washed with PBS and incubated with the 
TO-PRO-3 for nuclei counterstaining. After washing three 
times with Tween-20 0.1% v/v in TBS, the coverslips were 
mounted. Cells were examined under a Leica TCS SP 
laser-scanning confocal microscope (Leica Microsystems, 
Wetzlar, Germany) equipped with a 488-nm argon laser, a 
543-nm He-Ne laser, and a 63× oil immersion objective 
(HCX PL APO CS 63×/1.32–0.60; Leica). Data were 
acquired at room temperature (23°C) using the integrated 
Leica Confocal Software package; multicolor images were 
captured through sequential scanning.
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